Acerus Pharmaceuticals - ASP Stock Forecast, Price & News

Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men's and women's health. The company offers Natesto, a nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism; and Noctiva, a vasopressin analog indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least 2 times per night to void. It also engages in developing Lidbree, a short acting lidocaine formulation delivered through a proprietary device into the vaginal mucosal tissue; Stendra, a PDE5 inhibitor for the treatment of erectile dysfunction; Tefina, a clinical stage product for women with female sexual dysfunction; and Noctiva combination products, which are in the pre-clinical development stage for the treatment of benign prostatic hypertrophy, overactive bladder, and pediatric nocturnal enuresis. In addition, the company provides TriVair technology platform for pulmonary and nasal dosing. It sells its products through its salesforce in the United States and Canada; and through a network of distributors internationally. The company was formerly known as Trimel Pharmaceuticals Corporation and changed its name to Acerus Pharmaceuticals Corporation in September 2015. Acerus Pharmaceuticals Corporation was founded in 2008 and is headquartered in Mississauga, Canada.

Acerus Pharmaceuticals Trading Down 9.7 %

ASP Stock traded down C$0.27 during midday trading on Monday, hitting C$2.50. 595 shares of the company's stock were exchanged, compared to its average volume of 1,116. Acerus Pharmaceuticals has a 1-year low of C$1.69 and a 1-year high of C$10.00. The business has a 50-day simple moving average of C$2.99 and a two-hundred day simple moving average of C$1.91. The stock has a market capitalization of C$19.27 million and a PE ratio of -0.54. The company has a current ratio of 0.49, a quick ratio of 0.20 and a debt-to-equity ratio of 261.01.